Analysis of mortality risk factors in patients on the heart transplant waiting list: a retrospective study

Main Article Content

A. Yu. Melnyk
N. O. Yaschenko
H. I. Kovtun
I. M. Kuzmych
S. R. Maruniak
B. M. Todurov

Abstract

The aim – to analyze mortality risk factors among patients on the heart transplant waiting list in Ukraine.
Materials and methods. The study included 464 patients who were on the HT waiting list at the State Non-Profit Enterprise «Heart Institute of the Ministry of Health of Ukraine» between 2021 and 2024. Demographic parameters, HF etiology, urgency status, laboratory values, use of mechanical circulatory support (MCS), functional test results, and complications were analyzed. One-year survival was predicted using the Seattle Heart Failure Model (SHFM). Statistical analysis included Student’s t-test, Mann-Whitney test, Pearson’s χ2 test, and logistic regression (p<0.05).
Results. The mean age of patients was 49 (38; 58) years, with males comprising 82.8 % of the cohort. HT was performed in 89 (19.2 %) patients, with an average waiting time of 222±45 days. During the waiting period, 11 (2.73 %) patients required MCS implantation, 8 (1.72 %) developed pulmonary embolism, 53 (11.4 %) experienced congestive pneumonia, 27 (5.82 %) had a stroke, 48 (10.3 %) developed gastrointestinal bleeding, and 29 (6.25 %) required dialysis. The overall mortality rate was 21.1 % (98 patients). Deceased patients were significantly older (54 (40; 63) years vs. 47 (33; 58) years, p=0.011), more frequently classified as NYHA functional class IV (35.7 % vs. 14.8 %, p=0.0001), and were more likely to have a diagnosis of dilated cardiomyopathy (80.6 % vs. 62.8 %, p=0.005). Blood group AB was more prevalent among deceased patients (8.16 % vs. 1.37 %, p=0.0003), as well as a history of cardiac surgery (19.4 % vs. 9.86 %, p=0.010) and a longer waiting time (291 (147; 672) vs. 204 (101; 494) days, p=0.0011). Additionally, intra-aortic balloon pump support was more frequently used in the deceased group (3.06 % vs. 0.00 %, p=0.008), indicating a more critical condition.
Conclusions. The main mortality risk factors among heart transplant waiting list patients in Ukraine include age, NYHA functional class IV, dilated cardiomyopathy, blood group AB, prior cardiac surgery, and longer waiting time.

Article Details

Keywords:

heart transplant waiting list, heart transplantation, chronic heart failure, mortality

References

Bounader K, Flécher E. End-stage heart failure: The future of heart transplant and artificial heart. Presse Med. 2024 Mar;53(1):104191. https://doi.org/10.1016/j.lpm.2023.104191

Jacob S, Garg P, Wadiwala I, Yazji JH, Alomari M, Alamouti-Fard E, Akram Hussain MW, Pham SM. Strategies for Expanding Donors Pool in Heart Transplantation. Rev Cardiovasc Med. 2022 Aug 15;23(8):285. https://doi.org/10.31083/j.rcm2308285.

Rana A, Gruessner A, Agopian VG, et al. Survival benefit of solid-organ transplant in the United States. JAMA Surg. 2015;150(3):252-259. https://doi.org/10.1001/jamasurg.2014.2038

Park SJ, Milano CA, Tatooles AJ, et al.; HeartMate II Clinical Investigators. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail. 2012;5(2):241-248. https://doi.org/10.1161/CIRCHEARTFAILURE.111.963991

Bakhtiyar SS, Godfrey EL, Ahmed S, Lamba H, Morgan J, Loor G, Civitello A, Cheema FH, Etheridge WB, Goss J, Rana A. Survival on the Heart Transplant Waiting List. JAMA Cardiol. 2020 Nov 1;5(11):1227-1235. https://doi.org/10.1001/jamacardio.2020.2795

Baumwol J. «I Need Help» – A mnemonic to aid timely referral in advanced heart failure. J Heart Lung Transplant. 2017 May;36(5):593-594. https://doi.org/10.1016/j.healun.2017.02.010

Jeffries N, Miller MA, Taddei-Peters WC, Burke C, Baldwin JT, Young JB. What is the truth behind pump thrombosis in the HeartMate II device? A National Heart, Lung, and Blood Institute perspective based on data from the Interagency Registry for Mechanically Assisted Circulatory Support. J Heart Lung Transplant. 2015 Dec;34(12):1505-10. https://doi.org/10.1016/j.healun.2015.10.036

Hunt SA, Haddad F. The changing face of heart transplantation. J Am Coll Cardiol. 2008;52(8):587-598. https://doi.org/10.1016/j.jacc.2008.05.020

Goldstein BA, Thomas L, Zaroff JG, Nguyen J, Menza R, Khush KK. Assessment of Heart Transplant Waitlist Time and Pre- and Post-transplant Failure: A Mixed Methods Approach. Epidemiology. 2016 Jul;27(4):469-76. https://doi.org/10.1097/EDE.0000000000000472

Rudolf H, Mügge A, Trampisch HJ, Scharnagl H, März W, Kara K. NT-proBNP for risk prediction of cardiovascular events and all-cause mortality: The getABI-study. Int J Cardiol Heart Vasc. 2020 Jun 5;29:100553. https://doi.org/10.1016/j.ijcha.2020.100553

Echouffo-Tcheugui JB, Zhang S, Daya N, McEvoy JW, Tang O, Juraschek SP, Ndumele CE, Coresh J, Christenson RH, Selvin E. NT-proBNP and All-Cause and Cardiovascular Mortality in US Adults: A Prospective Cohort Study. J Am Heart Assoc. 2023 Jun 6;12(11):e029110. https://doi.org/10.1161/JAHA.122.029110

Izhakian S, Frajman A, Freidkin L, Shtraichman O, Rosengarten D, Pertzov B, Barac YD, Kramer MR. Prognostic Significance of the N-Terminal Pro-B-Type Natriuretic Peptide in Lung Transplant Candidates on the Waiting List. Diagnostics (Basel). 2022 Aug 31;12(9):2112. https://doi.org/10.3390/diagnostics12092112